Verition Fund Management
TEVA icon

Verition Fund Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Verition Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-204,300
Closed -$6.38M – 3497
2025
Q4 		$6.38M Sell
204,300
-125,900
-38% -$3.1M 0.03% 710
2025
Q3 		$6.67M Sell
330,200
-27,800
-8% -$488K 0.03% 851
2025
Q2 		$6M Buy
358,000
+119,600
+50% +$1.93M 0.03% 941
2025
Q1 		$3.66M Buy
238,400
+188,500
+378% +$3.37M 0.02% 1085
2024
Q4 		$1.1M Sell
49,900
-7,000
-12% -$127K ﹤0.01% 1982
2024
Q3 		$1.03M Buy
56,900
+1,100
+2% +$19.3K 0.01% 1874
2024
Q2 		$907K Buy
55,800
+12,400
+29% +$191K 0.01% 1728
2024
Q1 		$612K Buy
+43,400
New +$547K ﹤0.01% 1902
2017
Q3 		– Sell
-40,000
Closed -$1.33M – 1368
2017
Q2 		$1.33M Buy
40,000
+17,000
+74% +$526K 0.13% 136
2017
Q1 		$738K Buy
+23,000
New +$785K 0.07% 380

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Verition Fund Management's TEVA Position: Q2 2026 in Review

Verition Fund Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 35% in Q2 2026, selling an estimated $157K and leaving 8,649 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

Verition Fund Management first reported a position in TEVA in Q3 2015 and has held it in 25 quarters since. The position peaked at $9.45M in Q4 2025. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Verition Fund Management held 8,649 shares of Teva Pharmaceutical Industries Limited worth $293K as of Q2 2026.
  • Verition Fund Management sold 4,713 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $157K.
  • Teva Pharmaceutical Industries Limited made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1764 holding.
  • Verition Fund Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2015 and has held it in 25 quarters since.
  • Verition Fund Management's Teva Pharmaceutical Industries Limited position peaked at $9.45M in Q4 2025.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.